Gsk (GSK) Net Income (2009 - 2026)

Over the twelve months ended Sep 30, 2026, Gsk's Net Income came in at $2.75 billion, down 70.9% year-over-year; for the year ended Dec 31, 2025, it was $8.29 billion, up 119.8% from the prior year.

• Net Income has a five-year compound annual growth rate of 0.2% (years ended Dec 2020 to Dec 2025).
• By year, Net Income came in at $3.77 billion in the year ended Dec 31, 2024 (-42.9%), $6.6 billion in the year ended Dec 31, 2023 (-65.8%), $19.33 billion in the year ended Dec 31, 2022 (+175.7%) and $7.01 billion in the year ended Dec 31, 2021 (-14.5%).
• Five-year quarterly Net Income spans a low of -$2.85 billion in the quarter ended Dec 31, 2025 and a high of $15.45 billion in the quarter ended Dec 31, 2022.
• Year over year, Net Income gained in four of the last six quarters, with growth averaging 3.8%.
• The high point for year-over-year Net Income in five years was the quarter ended Dec 31, 2021 (growth of 744.3%); the low point was the quarter ended Dec 31, 2023 (a decline of 96.8%).
• Per Business Quant data, the three quarters before the quarter ended Sep 30, 2026 came in at $207.96 million (quarter ended Jun 30, 2026), $2.48 billion (quarter ended Mar 31, 2026) and -$2.85 billion (quarter ended Dec 31, 2025).